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Effects of Phthalic Acid Esters on the Liver
and Thyroid*
by Richard H. Hinton,t Fiona E. Mitchell,t Alan Mann,t
Dawn Chescoe,t Shirley C. Price,t Alistair Nunn,t Paul
Grasso,t and James W. Bridgest
The effects, over periods from 3 days to 9 months of administration, of diets containing di-2-ethylhexyl
phthalate are very similar to those observed in rats administered diets containing hypolipidemic drugs
such as clofibrate. Changes occur in a characteristic order commencing with alterations in the distribution
of lipid within the liver, quickly followed by proliferation of hepatic peroxisomes and induction of the
specialized P450 isoenzyme(s) catalyzing w oxidation of fatty acids. There follows a phase of mild liver
damage indicated by induction of glucose-6-phosphatase activity and a loss of glycogen, eventually leading
to the formation of enlarged lysosomes through autophagy and the accumulation of lipofuscin. Associated
changes are found in the kidney and thyroid. The renal changes are limited to the proximal convoluted
tubules and are generally similar to changes found in the liver. The effects on the thyroid are more marked.
Although the levels of thyroxine in plasma fall to about half normal values, serum triiodothyronine remains
close to normal values while the appearance of the thyroid varies, very marked hyperactivity being noted
7 days after commencement of treatment, this is less marked at 14 days, but even after 9 months treatment
there is clear cut evidence for hyperactivity with colloid changes which indicate this has persisted for
some time. Straight chain analogs of di-2-ethylhexyl phthalate, di-n-hexyl phthalate and di-n-oxtyl phthal-
ate differ entirely in their short-term effects on the liver and kidney but have similar effects on the thyroid.
The short-term in vivo hepatic effects of the three phthalate esters can be reproduced in hepatocytes in
tissue culture. All three phthalate esters, as well as clofibrate, have early marked effects on the metabolism
of fatty acids in isolated hepatocytes. The nature of these changes is such as to increase storage of lipid
in the liver. A hypothesis is presented to explain the progress from these initial metabolic effects to the
final formation of liver tumors.
Introduction
The demonstration that a significant increase in liver
cancer in rats and mice occurs after administration of
diets containing excessive amounts of di(2-ethylhexyl)
phthalate (1) has raised concern regarding its effects on
human health. This result was not totally unexpected,
as the short-term hepatic effects ofDEHP which include
hepatomegaly and proliferation of peroxisomes had al-
ready been reported to occur with certain hypolipidemic
drugs (2) exemplified by clofibrate, which were known
to be hepatocarcinogenic in rats (2-4).
Several surveys indicate that clofibrate, although ad-
ministered to humans at up to 10% of the rat carcino-
genic dose for up to 15 years, does not increase the
incidence of liver cancer in humans (5,6) and that the
short-term effects on human liver are markedly differ-
ent from the effects on rats (7,8). Accordingly it has
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been argued that the group of nonmutagenic hepato-
carcinogens, which cause proliferation of liver peroxi-
somes in rodents typified by clofibrate and including
DEHP, does not pose any risk to humans.
As it is not possible to study the livers of humans
deliberately exposed to various doses of environmental
pollutants such as DEHP, it is necessary to use some
indirect methods to test this assertion of safety to hu-
mans, for example by: determining which short-term
changes in the liver of rats treated with DEHP are
directly connected with the development of liver cancer;
developing conditions for culturing rat liver hepatocytes
in which these in vivo changes could be reproduced and;
testing the response of human hepatocytes under sim-
ilar conditions. A further independent question is
whether the response of rats to DEHP is typical oftheir
response to phthalate esters as a class.
Carpenter and his colleagues (9) reported in 1953 that
hepatomegaly occurred in rats but not guinea pigs or
dogs administered diets containing DEHP. There is,
however, little change in the results of standard liver
function tests in any species (10). Apart from the in-
crease in size, the most noticeable change in the liver
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is a very marked increase in the number of peroxisomes
in the hepatocytes of rats (11-14), although not of
guinea pigs (15) or ferrets (16). Both rats (11) and ferrets
16) show some dilation of the endoplasmic reticulum
after treatment with DEHP but the main specific en-
doplasmic reticulum change in rats treated with DEHP,
as in rats treated with clofibrate (17) is a very marked
induction of the specific P-450 isoenzyme(s) catalyzing
the w-oxidation of fatty acids. It has been reported that
in rat hepatocytes mitochondria are increased in number
by DEHP but that there is no effect in vivo on mito-
chondrial respiratory activity. Lake et al. (11) also re-
ported a reduction in succinate dehydrogenase activity;
this would appear to be variable between strains be-
cause in our experiments the decrease was less pro-
nounced and was not statistically significant (14). We
did, however. observe a change in the appearance of
mitochondria under the electron microscope. Various
studies have been made of the effect of phthalate esters
on mitochondria in vitro. These have not provided much
useful toxicological information to date partly because
the authors have often failed to consider that in the
living animal the liver is exposed to the monoester and
its metabolites rather than DEHP itself and partly be-
cause nonspecific damage can arise due to the fact that
long-chain alkyl monoesters of phthalic acid are surface-
active.
As well as producing morphological change in the
liver, peroxisome proliferating agents produce changes
in other organs and in plasma components. For example,
in the kidney of rats treated with hypolipidemic drugs
there are alterations in the cells of the proximal tubule
similar to those observed in hepatocytes (18). Changes
are also evident in the testes. DEHP also produces al-
terations in plasma components; in particular, there is
a marked reduction in plasma triglyceride with a smaller
change in plasma cholesterol (19). Additionally there
may be slight changes in carbohydrate metabolism as
indicated by alteration in plasma glucose (19,20).
In regard to the question of the comparability of the
effects of DEHP and other phthalates much more data
are available on the effects of DEHP on rats than on
other phthalate esters. Several other phthalic acid es-
ters have been reported to cause hepatomegaly in vivo
(20). Gray et al. (21) have shown that a variety ofphthal-
ate esters other than DEHP can induce a small degree
of peroxisome proliferation in hepatocytes in tissue cul-
ture. Diethyl and dibutyl phthalate also modify the ac-
tion of drug-metabolizing enzymes (22-24) but not glu-
cose-6-phosphatase activity (24). Dibutyl phthalate, like
DEHP, is reported to lower plasma cholesterol and in-
hibit cholesterogenesis (25,26), while diethyl phthalate,
like DEHP, lowers plasma triglyceride but unlike
DEHP does not affect hepatic peroxisomes (12).
From the limited data available it can be deduced that
there are marked differences in the various effects of
phthalate esters on rat livers, but the literature does
not provide sufficient evidence to deduce whether these
were qualitative or merely quantitative differences.
Materials and Methods
Di(2-ethylhexyl) phthalate (DEHP), mono(2-ethyl-
hexyl) phthalate (MEHP), di(n-octyl) phthalate
(DnOP), mono(n-octyl) phthalate (MnOP), di(n-hexyl)
phthalate (DnHP), and mono(n-hexyl) phthalate
(MnHP) were donated by BP chemicals (Sully, Penarth,
UK). The hypolipidemic drugs fenofibrate and clofibrate
were kindly donated by Laboratories Fournier (Dijon,
France) and ICI Pharmaceuticals (Alderley Edge,
Cheshire, UK). Clofibric acid, chlorpromazine and fatty
acid-poor fraction 5 bovine serum albumin were pur-
chased from the Sigma Chemical Co. Ltd. (Poole Dor-
set, UK). Liebowitz L15 culture medium, fetal calf
serum, and Kanamycin were purchased from Flow Lab-
oratories Ltd. (Irvine, Scotland). Collagenase was pur-
chased from the Boehringer Corporation (Lewes, Sus-
sex, UK) and [1-14C] palmitate (58.3 mCi/mmole) was
purchased from Amersham International Ltd. (Amer-
sham, Bucks, UK).
In Vivo Studies
Male and female Wistar albino rats were used, except
for a single experiment in which the response of Wistar
Albino rats and University of Surrey hooded rats to
peroxisome proliferating agents was compared. The
rats were obtained either from the University of Surrey
Rodent Breeding Unit or from ICI Pharmaceuticals Di-
vision. Animals were weighed, inspected, divided at
random into control and experimental groups, and
transferred from Spratts pelleted diet I to Spratts pow-
dered diet II-expanded (Spratts Ltd., Barking, Essex,
UK). After a period of one week, which served to ac-
custom the rats to powdered diets the animals were
transferred to experimental diets as follows.
Experiment 1. Male Wistar albino rats of the Uni-
versity of Surrey strain weighing initially between 85
and 115 g were used in this experiment. The rats were
divided into four groups which received control diet or
diet containing 2% w/w of DEHP, DnHP, or DnOP cor-
responding approximately to 2000 mg/kg/day. Groups
of six control rats and four rats from each experimental
group were killed 3, 10, and 21 days after initial offering
of the diet.
Experiment 2. Male and female Wistar albino rats
of the ICI strain weighing initially about 200 g were
used in this experiment. The rats were divided into four
groups respectively which received control diet or diet
containing 0.05%, 0.2%, or 1.0% w/w of DEHP corre-
sponding approximately to 50, 200, and 1000 mg/kg/day.
Groups of six control rats and four rats from each ex-
perimental group were killed 3, 7, 14, 28 days and 9
months after initial offering the diet.
Experiment 3. Male Wistar albino rats of the ICI
strain aged approximately nine months and weighing
750-800 g were used in this experiment. The rats were
divided into four groups which received respectively
control diet or diets containing DEHP, clofibrate, or
fenofibrate at concentrations designed to produce re-
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spectively intakes of 1000, 400, and 200 mg/kg/body
weight/day. The rats did not take as readily to the ex-
perimental diets as did younger rats. The diet con-
sumption and compound intake for the two periods are
presented in the Results section. Groups of four control
rats and four rats from each experimental group were
killed 3 and 13 days after initial offering of the com-
pounds.
Experiment 4. Male Wistar albino rats of the Uni-
versity of Surrey strain were used in this experiment.
The rats were divided into three groups which received
respectively control diet or diets containing 0.4% w/w
clofibrate or 1% w/w DEHP. Six control rats and six
rats from each experimental group were killed 3, 10,
and 21 days after initial offering of the diets.
Experiments 5, 6, and 7. University of Surrey Wis-
tar albino rats were used in experiments 5 and 6, which
respectively received control diet, diets containing clo-
fibrate to ensure the intake of 400 mg/kg/day or feno-
fibrate to provide either 13 mg/kg/day, 60 mg/kg/day,
or 200 mg/kg/day. Group of six control rats and four
rats from each experimental group were killed, in ex-
periment 5 after 24 hr and in experiment 6 after 3, 7,
14, 28 days, 8, 12, and 20 weeks, or 6, 9, 12, and 18
months. In experiment 7 groups of Wistar albino rats
and hooded rats were administered diets containing
0.4% clofibrate or 0.2% fenofibrate corresponding to
drug intake of 400 or 200 mg/kg/day. Groups of six con-
trol rats and four rats from each experimental group
were killed 14 days after initial offering of the diet.
In Vitro Studies
Hepatocytes were isolated by an adaption of the
method of Rao et al. (27). The cells were then either
resuspended at a concentration of 2 x 106 cells/mL in
bicarbonate-poor Hanks solution, pH 7.4, containing
1.23 mM CaCl2 and used immediately, or, resuspended
in Liebowitz L15 medium containing 10% fetal calf
serum, 2mM glutamine, 10% tryptose-phosphate broth,
100 g/mL Kanamycin, 10-6M insulin and 10-5M hydro-
cortisone and seeded (2 x 106 cells in 4 mL medium) in
40 mL Falcon Primaria tissue culture flasks (Becton
Dickinson and Co., Oxford). Cultures were incubated
at 37°C. The medium was changed 2-4 hr after seeding
and subsequently every 24 hr. Test compounds were
dissolved in dimethylformamide. The volume added was
such that the dimethylformamide concentration was
never greater than 0.04% v/v. After incubation the cells
were harvested into 1 mL of 0.25 M sucrose containing
5 mM EDTA and 5 mM Tris HCI, pH 7.4, and homog-
enized by sonication.
Preparation of Tissues; Chemical and
Enzyme Determination
Preparation of tissue for light microscopy and details
of the preparation of samples for electron microscopy
are given elsewhere (14). Briefly, samples for light mi-
croscopy were fixed in phosphate buffered formalin and
samples for electron microscopy were fixed in 4% glu-
taraldehyde, counterfixed in 2% osmic acid, embedded,
cut and counterstained with lead and uranyl acetate as
described previously.
Livers were homogenized in 0.25 M sucrose contain-
ing 5 mM Tris, pH 7.4, with a Potter-Elvejem homog-
enizer. The large particulate fraction (150,000g-min pel-
let) and the microsomal fractions were prepared as
described by Mann et al. (14). Protein and enzyme es-
timation were carried out as described by Mann et al.
(14) unless otherwise stated. DNA was estimated by
the method of Burton (28) and cytochrome P-450 and b5
by the method of Omura and Sato (29). Uricase (30),
laurate hydroxylase (31) and ethoxycoumarin deeth-
ylase (32) were measured by standard methods. 1-D-
Galactosidase was measured as described by Hinton and
Norris (33) and lactate dehydrogenase according to
Bergmeyer (34).
Results
This paper summarizes a program ofwork carried out
in our laboratories over the last four years, designed to
elucidate the hepatic changes which lead to the induction
of tumors in rats treated with DEHP and with other
peroxisome-proliferating agents. Clearly, it is impos-
sible to present all our results here in detail. We have,
accordingly, presented only in summary the results of
experiments where detailed descriptions will be avail-
able in papers either in the press or which have already
been accepted for publication.
Experiment 1 (Comparison of Effects of
Diets Containing DEHP and of the
Equivalent Straight-Chain Esters of
Phthalic Acid)
The aim of this experiment, described in detail else-
where (14), was to determine whether the straight-
chain phthalate esters DnOP and DnHP produced in
rats hepatic changes similar to those caused by DEHP.
The results, summarized in Table 1, show clearly that
this is not the case. Treatment with DEHP caused a
marked proliferation of peroxisomes, induction of w-
oxidation of fatty acids and a rapid accumulation of fat
in small droplets apparently concentrated in the peri-
portal zone. DnOP and DnHP, by contrast, did not in-
duce peroxisome proliferation or w-oxidation of fatty
acids but did cause a slowly developing but very marked
accumulation of fat in the centrilobular zone of the liver
with evidence of fatty necrosis 21 days after commence-
ment of treatment. In a separate experiment we found
that the changes in rat liver caused by administration
of diets containing 2% DnOP and DnHP are qualita-
tively similar to, although somewhat more severe than,
those found in rats treated with diets containing 0.025%
w/w chlorpromazine (35,36).
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Table 1. Summary of morphological changes in the livers of rats
administered diets containing 2% w/w DEHP, DnOP, or DnHP.
Treatment
Effect DEHP DnHP DnOP
Hepatomegaly + + +a +b +b
General appearance of liver Dark Light, Light,
greasy greasy
Centrilobular loss of + + + +
glycogen
Total glycogen loss after 21 ++C
days treatment
Centrilobular necrosis - + + + +
Periportal fat accumulation +
Centrilobular fat - + +
accumulation
Peroxisome proliferation + + + b+b + b
Smooth endoplasmic + + + +
proliferation
Loss of rough endoplasmic + + +
reticulum
Increased density of inner + +
mitochondrial matrix
Initial burst of mitosis + +- -
a Degree of change seen when compared to age-matched controls.
b Visible after 21 days but not at earlier times.
c Lesion absent.
Experiments 2, 5, 6, and 7 (Dose- and
Time-Response Studies on Young Rats
Administered DEHP or Hypolipidemic
Drugs)
The aim ofthese experiments was firstly to determine
the dose dependence and the time course of the changes
observed in the livers of rats treated with DEHP or
with the hypolipidemic drugs clofibrate and fenofibrate,
and secondly to determine whether there were signifi-
cant differences between the responses of male and fe-
male rats. Detailed accounts of experiments 2 and 5
have been published elsewhere (37,38), and the results
are summarized in Table 2. Study of the time course of
the alterations showed that the changes could be divided
into four groups: changes which occurred immediately
after commencement of treatment but which then re-
versed to the control situation (stage 1), changes which
were fully developed by 3 days and which were main-
tained through the whole period of diet administration
(stage 2), changes which developed more slowly but
which were fully established by 28 days after com-
mencement of treatment (stage 3), and very slowly de-
veloping changes (stage 4). The parameters which fall
into these groups are as follows.
Stage 1. Initially there was a very marked increase
in the rate of incorporation of 3H thymidine into DNA
(Fig. 1A). In rats treated with 200 or 1000 mg/kg/day
ofDEHP the increase was most marked at 3 days, while
in rats treated with 50 mg/kg/day the increase was most
pronounced at 7 days. In each case, by 28 days the rate
of 3H thymidine incorporation had fallen to below con-
trol levels. The increase in incorporate of 3H thymidine
into DNA was due to synthesis preceding cell divisions
rather than repair as the number of mitotic figures vis-
ible by light microscopy increased in parallel (Fig. 1A).
There was also an increased incidence of myelin figures
in bile canaliculi at 3 days but not at subsequent times,
and this linked to a transient increase in bile flow.
Stage 2. The increase in the peroxisomal enzymes
responsible for cyanide-insensitive palmitoyl CoA oxi-
dation, particulate a-glycerophosphate dehydrogenase
activity, and the P-450 isoenzyme catalyzing laurate w-
hydroxylation were all markedly induced after 3 days
of treatment and showed little or no further change at
subsequent times. Catalase showed a similar pattern as
did the number of peroxisomes seen in male rats. In
female rats, on the other hand, the number of peroxi-
somes did not appear to change greatly in spite of a
very marked induction of palmitoyl CoA oxidation. This
suggests that much of the increase in activity may have
been due to microperoxisomes which are indistinguish-
able morphologically from endoplasmic reticulum ele-
ments unless stained for peroxidase activity.
Stage 3. The endoplasmic reticulum enzyme glu-
cose-6-phosphatase showed a time- and dose-dependent
fall in activity, minimum activities being reached at 14
days (Fig. 1C). A similar fall was found in rats treated
with hypolipidemic drugs; in the latter experiments his-
tochemical staining for glucose-6-phosphatase activity
was performed. This showed that the loss was specifi-
cally from cells in the centrilobular zone. As is fre-
quently the case centrilobular loss ofglycogen paralleled
the fall in glucose-6-phosphatase activity. In addition
the P450 isoenzymes responsible for ethoxycoumarin
deethylase activity were not altered at 3, 7, and 14 days
in male rats but were somewhat increased after 21 days.
In female rats the increase was greater and was ob-
served at both 14 and 28 days. Finally, in male rats a
marked hypertrophy arose as assessed by counting nu-
clear and measuring the DNA content/gram tissue. This
developed over the first 14 days. The effect was much
less marked in female rats.
Stage 4. The lysosomal enzyme ,-D-galactosidase
showed no change in activity between 3 and 28 days of
treatment but was markedly induced at 9 months (Fig.
1D). The increase in this enzyme activity was paralleled
by an increase in the number and size of lysosomes and
the formation of lipofuscin deposits. Experiments using
hypolipidemic drugs show that the enlarged lysosomes,
which have the same staining properties as the lipofus-
cin deposits, appear after about 8 weeks of treatment
but that the lipofuscin deposits did not form until the
animals have been receiving these compounds for 6
months.
Three further observations do not fit neatly into the
pattern listed above. First, the percentage of catalase
activity recovered in the large particulate fraction fell
in rats treated with 1000 mg/kg/day of DEHP but rose
in rats treated with 50 mg/kg/day. As discussed else-
where (38), we believe this to be due to damage to the
membranes of the peroxisomes. Second, the overall lev-
els of cytochrome P-450 rose above control levels at 3
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Table 2. Changes in liver enzymes and cellular constituents in male and female Wistar albino rats (ICI strain) treated with varying
doses of di(2-ethylhexyl) phthalate or clofibrate.a
DEHP
Male Female Clofibrate,
50 mg/ 200 mg/ 1000 mg/ 50 mg/ 200 mg/ 1000 mg/ 400 mg/kg/
kg/day kg/day kg/day kg/day kg/day kg/day day
Body weight, g 102 98 93 101 92 91 101
Liver weight, g 113* 129* 155* 111 106 127* 151
Palmitoyl CoA oxidation 162* 257* 568* 137 205* 550* > 300*b
a-Glycerophosphate dehydrogenase 215* 299* 336* 156 205* 310*
Catalase 100 109 122* 100 109 137* 162*
Uricase 94* 78* 89* 100 100 106
% Catalase sedimentable
Glucose-6-phosphatase 91 77* 50* 80* 77* 60* 51*
Cytochrome P-450 110 120 135 111 102 117* 176*
Cytochrome b5 130 115* 117 104 115 116 99
Laurate hydroxylase 220* 362* 479* 164* 193* 311* 795*
Ethoxycoumarin deethylase 102 114* 110* 148* 151* 193*
,B-D-galactosidase 119 115 189* 126 133* 187* 216*
Nonprotein SH 125 87* 68* 68* 81* 88 66*
a For comparative purposes changes in these parameters in Wistar albino rats of the University of Surrey strain are shown. The results are
presented as percentage of control values and are the mean of values obtained after treatment for 14 and 28 days with the exception of the
value for P-D-galactosidase which is the change after treatment for 9 months. The results have been abstracted from our published work
(37,38).
b Only determined after 24 hours and 18 months treatment.
*Significantly different from control (p < 0.05).
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and 7 days but fell back to below control levels at later
times. We consider that the initial increase in total P-
450 is due to the induction of the specific P-450 isoen-
zyme responsible for laurate hydroxylation and that the
subsequent loss in activity is due to a loss in the P-450
isoenzymes arising from subtle damage to centrilobular
hepatocytes. This is probably the cause of the loss of
glucose-6-phosphatase activity and of glycogen. Third,
there are marked changes in lipid distribution. In ani-
mals treated for three days with 50 mg/kg/day ofDEHP
there was an overall increase in fat. With increasing
time or dose the fat clears from the vicinity ofthe central
vein resulting in an apparent periportal accumulation.
In experiments with hypolipidemic drugs a similar bi-
phasic change was apparent and, in this case, was so
great that at certain times and doses all the fat disap-
peared from the liver. We interpret these data as show-
ing that DEHP and hypolipidemic agents initially induce
the accumulation of lipid within hepatocytes, and it is
the subsequent induction of peroxisomes, known to be
concentrated in the centrilobular area (39), that is re-
sponsible for the clearance of the fat.
The conclusion from experiment 2 was that the
changes in the livers of rats treated with DEHP do show
a distinct time sequence. The findings also demonstrate
that the changes which occur in rats treated with DEHP
are identical to the changes which occur in the livers of
rats treated with the hypolipidemic drugs clofibrate and
fenofibrate (Table 2). Thus 1000 mg/kg/day of DEHP
produced qualitative and quantitative changes similar
to those found in rats treated with 400 mg/kg/day of
clofibrate or 60 mg/kg/day of fenofibrate. Finally, the
response of female rats to DEHP was for most param-
eters qualitatively similar to that of male rats but quan-
titatively slightly less. The exceptions are that although
the female rats showed less hepatocellular hypertrophy
and, accordingly, less hepatomegaly, there was greater
induction of ethoxycoumarin deethylase activity in fe-
male rats than in males and that initially in female rats
the induction of peroxisomal enzymes was not matched
by an increase in the number of peroxisomes recogniz-
able by electron microscopy without special staining.
The results of experiment 7, designed to examine
possible differences in response between the Wistar al-
bino and hooded rats, were assessed solely by exami-
nation of the gross pathology and by light and electron
microscopy. No significant difference between the two
strains was detected.
Experiment 3 (Examination of the Effects
of DEHP or Hypolipidemic Drugs on
Mature Rats)
This experiment was carried out to determine
whether the response of fully mature male rats to treat-
ments with DEHP or with hypolipidaemic drugs was
the same as that of the adolescent animals normally
employed in toxicological studies. The susceptibility of
both rats (40) and humans (41) to hepatotoxins often
varies with age and, indeed, age changes (and lowers)
the ability of the rat liver to hydrolyze DEHP to MEHP
(42), although the relevance of the last observation to
rats administered DEHP in the diet must be open to
doubt as in this case most hydrolysis occurs in the gut
(43,44).
Mature animals, unlike the adolescent animals used
in previous studies, did not take readily to the experi-
mental diet. Food consumption was less than that of
control rats resulting in a slight loss of body weight
(Table 3). However, after 3 days there was a significant
increase in relative liver weight in all groups of exper-
imental rats (Table 3). Examination of sections of liver
stained with hemotoxylin and eosin showed no signifi-
cant difference between experimental and control rats
after 3 days of treatment. However, after treatment
for 13 days there was slightly increased centrilobular
eosinophilia in all groups of rats as compared to the
control groups. There was no increase in the number of
mitotic figures in any treatment group. In all treated
groups there was a marked glycogen loss principally
from the centrilobular areas which was most notable
after 13 days of treatment. The distribution of neutral
fats also showed a clear dose response. After 3 days of
treatment the animals showed a periportal accumulation
of fat which became more marked after 13 days. The
animals treated with fenofibrate showed an almost total
loss of lipid from the liver lobule after treatment for 13
days.
Electron microscopic examination (Fig. 2) of the liv-
ers of rats treated with fenofibrate, clofibrate, and
DEHP revealed changes after only 3 days of treatment.
The degree of change was compound-related; fenofi-
Table 3. Effect of the administration of diets containing
fenofibrate, clofibrate, or DEHP on food consumption, body
weight, and liver weight of mature (9 month old) rats.
Control Fenofibrate Clofibrate DEHP
Food consumption, g consumed/rat/day
0-3 days 21.46 20.56 10.00 15.40
3-13 days 24.61 16.80 11.46 16.50
Additive consumed, mg/kg/daya
0-3 days 191 101 446
3-13 days - 140 183 781
Body weight'
3 days 771 t 19 93 (3) 85 (3)* 97
13 days 775 ±31 87 73 88
Absolute liver weightc
3 days 20.06 t 1.96 127 73 110
13 days 20.72 t 1.22 106 74 111
Relative liver weightd
3 days 0.026 t 0.003 136* 85 114
13 days 0.029 t 0.001 121* 101 126*
a Additive consumed is presented as mg additive consumed/kg body
weight/day.
bBody weight is presented as weight(g) ± standard error for con-
trol group, the results from treated groups are presented as% control.
c Absolute liver weight is presented as weight (g) t standard error,
for control groups and as % control for treated groups.d Relative liver weight is presented as the liver weight as a % of
body weight ± standard error for control groups, and as % of control
for treated groups.
* Significantly different from control.
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FIGURE 2. Sections from livers of (a) 9-month-old control rat and (b) the liver of a 9-month-old control rat fed a diet containing sufficientDEHP to ensure an intake of approximately 600 mg/kg/day for 21 days. (N) nucleus; (M) mitochondria, (P) peroxisome, (L) lysosome and(rer) rough endoplasmic reticulum.
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brate showed the greatest degree of alteration followed
by clofibrate and DEHP. There was a marked increase
of peroxisomes, and many of these peroxisomes lacked
the "core" seen in peroxisomes of control animals. There
were also changes in mitochondria consisting of in-
creased density of the inner mitochondrial matrix and
swelling with loss of internal structure. The treated
animals showed proliferation of the smooth endoplasmic
reticulum and disorganisation, dilation and degranula-
tion of the rough endoplasmic reticulum. There was also
an increase in the number of lipid droplets compared
with controls with all agents. This was most marked in
animals treated with DEHP. Examination of the livers
of animals treated for 13 days with these hypolipidemic
compounds showed that the effect found at 3 days all
persisted with the exception that there were fewer lipid
droplets in the treated animals than at the earlier time
although there was still an increase as compared to con-
trol animals.
The peroxisome-associated enzyme, cyanide-insensi-
tive palmitoyl CoA oxidase, was significantly induced
after only 3 days of treatment with fenofibrate (Table
4). By 13 days all treatment groups showed a significant
induction of this enzyme. Total catalase was signifi-
cantly induced in animals treated with DEHP and fen-
ofibrate, whereas with clofibrate the apparent increase
in activity was not statistically significant. Changes in
the distribution of catalase activity were less clear cut.
The specific activity of catalase in the particulate frac-
tions was decreased after 13 days of treatment in both
groups treated with fenofibrate and clofibrate, although
the decrease was only significant in rats treated with
fenofibrate; rats treated with DEHP showed no appar-
ent change.
Table 4. Effect of the administration of diets containing
fenofibrate, clofibrate, or DEHP on liver enzymes of mature
rats.'
Time Control Fenofibrate Clofibrate DEHP
Total catalase activity, units/mg homogenate/min
3 days 1.53 ± 0.12 113 89 100
13 days 1.71 ± 0.10 128* 112 121*
KCN-insensitive PCoA oxidase activity, nmole NAD + reduced/min/
kg protein
3 days 0.60 ± 0.03 282 305* 121
13 days 0.54 ± 0.06 712* 256* 424*
Glucose-6phosphatase activity, ,umole/min/mg homogenate protein
3 days 27.4 ± 2.4 77 102 83
13 days 31.4 ± 0.7 62* 92 67
Cytochrome P450 activity, nmole/mg microsomal protein
3 days 1.10 ± 0.03 118 85 118
13 days 0.70 ± 0.01 150 130 145
Laurate hydroxylase activity, units/mg microsomal protein
3 days 2.79 ± 0.26 267* 132* 216*
13 days 4.70 ± 0.43 312* 292* 266*
1-D-Galactosidase activity, p,mole/min/mg homogenate protein
3 days 3.31 ± 0.49 87 97 87
13 days 3.78 ± 0.25 81 79 98
'The intake of the compounds is as shown in Table 3. Results from
treated rats are presented as a percentage of control values. Control
results are presented as mean ± standard error.
* Significantly different from control (p < 0.05).
Three endoplasmic reticulum-associated enzymes
were measured. These were glucose-6-phosphatase, cy-
tochrome P-450, and the specialized P.450 enzyme lau-
rate hydroxylase. Glucose-6-phosphatase activity was
depressed in all treatment groups after 13 days although
the effect in animals given clofibrate was very small
(Table 4). A biphasic change was observed with cyto-
chrome P-450 in animals treated with fenofibrate or with
DEHP, i.e., an initial increase after 3 days of treatment
was followed by return to near control values after 13
days, although in animals treated with DEHP there
appeared to be a slight fall in enzyme activity to below
control value. The specific P-450 isoenzyme laurate hy-
droxylase was, however, induced in all treatment
groups (Table 4). The activity of the lysosomal enzyme,
,-D-galactosidase remained unaltered by treatment.
This result was consistent with the electron microscopic
results (Table 4).
Experiment 4 (Effects of DEHP and of
Analogous Straight-Chain Esters of
Phthalic Acid on the Thyroid)
In experiments with the hypolipidemic drugs fenofi-
brate and clofibrate we had previously observed a fall
in serum thyroxine (T4), although serum triiodothyron-
ine (T3) remained unaltered or even slightly increased
and the histological alterations in the thyroids were in-
dicative of hyperactivity (45). Examination of the thy-
roids of rats treated with DEHP for nine months
showed similar changes. Accordingly serum samples
collected in experiments 1 and 2 were reassayed, and
an additional experiment performed to examine alter-
ations in the thyroid after short periods of treatment
and to compare the response to DEHP and to the hy-
polipidaemic drug clofibrate showed a fall in plasma T4
after treatment with DEHP or its straight-chain ana-
logs di(n-hexyl) phthalate and di(n-octyl) phthalate
(DnOP) (Table 5) or with clofibrate (Table 6). The levels
of T3 in the plasma were, however, essentially unaf-
fected by treatment with any of these phthalate esters.
Table 5. Effect of administration of diets containing DEHP
(20,000 ppm), DnHP (20,000 ppm), or DnOP (20,000 ppm) on
triiodothyronine and thyroxine levels in rat serum.
Time of Experimentalb
treatment Parameter Controls DEHP DnHP DnOP
3 days T3 0.37 ± 0.07 (6) 89 62 73
T4 30 ± 6 (6) 66 53 47
10 days Ts 0.33 ± 0.08 (6) 79 109 91
T4 27 3 (6) 85 56 59
21 days T8 0.3 ± 0.05 (6) 140 183 133
T4 33 5 (6) 64 58 76
'Control results are presented as mean (>±g/L) ± standard error.
Value in parentheses is number of animals examined.
b Experimental results are presented as a percentage of control
values. Each experimental group consisted of four animals. Analysis
of variance showed a significant, treatment related decrease in T4
with all three phthalate esters but no significant effect on Ts.
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Table 6. Effect of administration of diets containing DEHP
(10,000 ppm) or clofibrate (4000 ppm) in triiodothyronine and
thyroxine levels in rat serum.
Time of Experimental
treatment Parameter Controla DEHPb Clofibrateb
7 days T3 0.37±0.05 (6) 54 41*
T4 33.3 ± 0.5 (6) 58 36*
21 days TS 0.32 ± 0.03 (6) 119 125
T4 31 ± 2 (6) 55* 65*
aControl results are presented as mean (Rg/L) ± standard error.
Values in parentheses are number of animals examined.
bExperimental results are presented as a percentage of control
values. Each experimental group consisted of six animals.
* Significantly different from control (p < 0.05).
Electron microscopic examination of the thyroids of
rats treated with DEHP or DnOP showed marked ul-
trastructural changes (Fig. 3); similar changes were
found in rats treated with DnHP. There was no signif-
icant difference between the effects ofthe different com-
pounds. In all cases there was a considerable increase
in the number and size of lysosomes. The Golgi appa-
ratus was also enlarged, and the mitochondria appeared
damaged. These alterations are very similar to those
seen in rats after administration of TSH (46), polychlo-
rinated biphenyls (47,48), or photomirex (49) and are
indicative of hyperactivity of the thyroid.
Experiments on Isolated Hepatocytes
In agreement with the work of other groups (50), we
found that treatment of cultured hepatocytes with
MEHP resulted in induction of cyanide-insensitive pal-
mitoyl CoA oxidation. Induction was clearly dose-de-
pendent. Maximal induction was observed at a dose of
0.25 mM. In contrast, no systematic change in cyanide-
insensitive palmitoyl CoA oxidation was seen in hepa-
tocytes treated with MnHP or, in agreement with Gray
et al. (21), in hepatocytes treated with MnOP. Hepa-
tocytes treated with 0.25 mM MnHP or MnOP, unlike
hepatocytes treated with 0.25 mM MEHP, showed signs
of systematic toxicity such as blebbing and vacuolation
although there was no increase in cell death as assessed
by leakage of lactate dehydrogenase into the medium.
Hepatocytes treated with the three phthalate esters
showed increased amounts of lipid accumulation, this
FIGURE 3a. Sections of the thyroids of a young (8-week-old) control rat. (N) nucleus; (Go) Golgi apparatus; (L) lysosome; (M) mitochondria;
(V) villi; (RER) rough endoplasmic reticulum; (RBC) red blood cell.
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FIGURE 3b. Sections of the thyroids of a young rat administered a diet containing 20,000 ppm of DEHP for 21 days. (N) nucleus; (Go) Golgi
apparatus; (L) lysosome; (M) mitochondria; (V) viAi; (RER) rough endoplasmic reticulum; (RBC) red blood cell.
was seen as small droplets around the margins of the
cell after treatment with MEHP, while cells treated
with MnHP or MnOP showed, in addition, some larger
some central droplets (51). No other signs of toxicity
such as a decrease in glucose-6-phosphatase activity or
glutathione nor any increase in H202 production were
observed in hepatocytes treated with MEHP (Table 7).
In view of the rapid increase in the amount of lipid
in hepatocytes after treatment in vivo or MEHP in
vitro, we decided to investigate whether MEHP and its
straight-chain analogs MnHP and MnOP interfered in
fat metabolism in freshly isolated hepatocytes. The re-
sults of these experiments have already been published
(51,52). In brief, we found that when hepatocytes were
isolated from fasted rats or in the early afternoon from
rats fed ad libitum, all three phthalic esters caused a
rapid and marked increase both in the incorporation of
1-r4C-palmitate into triglyceride and cholesterol esters
and an increase in fatty acid oxidation similar to that
already reported in rats treated with clofibrate (57),
whereas hepatocytes isolated from fed rats in the morn-
ing showed much smaller changes. In no case was there
any increase in the rate of export of lipoproteins.
The results obtained in these experiments were com-
pared with the results obtained in parallel experiments
with the parent acids (clofibric acid and fenofibric acid)
of the hypolipidemic drugs clofibrate and fenofibrate,
with ciprofibric acid or with trichloracetic acid, the per-
oxisome-proliferating (58) metabolite of trichlorethyl-
ene. The results obtained (59) showed that fenofibric
acid and ciprofibric acid interfered in lipid metabolism
in the same way as did clofibrate and MEHP. However,
although both fenofibrate acid and ciprofibrate acid are
more potent peroxisome proliferators than clofibric acid
or MEHP, the early effects on lipid metabolism were
not proportionally greater. Trichloracetic acid had no
significant effect, as might be expected from its struc-
ture.
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FIGURE 3c. Section of the thyroids of a young rat administered a diet containing 20,000 ppm of DnOP for 21 days. (N) nucleus; (Go) Golgi
apparatus; (L) lysosome; (M) mitochondria; (V) villi; (RER) rough endoplasmic reticulum; (RBC) red blood cell.
Table 7. Effect of MEHP on palmitoyl CoA oxidation, H202 release, glutathione, glutathione peroxidase, glucose-6-phosphatase, and
incorporation of 3H-thymidine into DNA in cultured rat hepatocytes.a
8H-Thymidine
CN--Independent Glutathione Glucose-6- incorporated,
palmitoyl CoA Glutathione, nmole/ peroxidase, units/ phosphatase, counts/min/mg
Addition to medium oxidation H202, nmole/mgb mg proteind mg nmole/mg/nine - protein'
Control 1.03 ± 0.03 (3) 14.8 ± 5.2 (4) 79.9 ± 9.6 (8) 0.30 ± 0.07 (4) 133 t 9 (7) 60 ± 10 (4)
0.05 mM MEHP 2.90 ± 0.57 (4)* 15.0 ± 5.4 (7) 107.6 ± 18.9 (8) 0.27 ± 0.05 (4) 136 ± 24 (4) 68 ± 9 (3)
0.1 mM MEHP 5.85 ± 0.27 (4)* 16.2 ± 3.1 (8) 84.2 ± 11.6 (8) 0.31 ± 0.02 (4) 138 6 (5) 51 6 (4)
0.25 mM MEHP 10.27 ± 0.30 (4)* 13.3 ± 2.1 (8) 114.6 ± 16.4 (8) 0.32 ± 0.04 (4) 144 ± 6 (4) 51 ± 4 (4)
'MEHP was dissolved in dimethylformamide (DMF) and added to the hepatocytes to give a final concentration of 0.04% v/v. An equivalent
volume of DMF was added to the control cultures. Details of the cell culture methods are as given elsewhere (52). Results are presented as
mean ± standard error (number of flasks).bAssayed according to Hildebrand et al. (53).
CAssayed according to Saville (54).
d Assayed- according to Thompson et al. (55).
eAssayed according to Neville and Arion (56).
fHepatocytes were incubated for 48 hr prior to addition of the compounds. After exposure f6r 24 hr to the compound 3H-thymidine was
added and incubated for Lh with the cells. Acid-insoluble radioactivity was used as a measure of DNA incorporation. In other experiments in
which the compounds were added 24 hr after plating the cells and then incubated for either 24 or 48 hr, no signifiant change in incorporation
was observed.
* Significantly different from control (p < 0.05).
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Discussion
Development of Hepatic Changes
As a result of these studies we would propose the
following mechanism for the development of liver dam-
age in rats treated with DEHP.
Following the hydrolysis of DEHP to MEHP in the
gut, the absorbed MEHP causes an inappropriate syn-
thesis of triglyceride in the liver. The most likely ex-
planation for this, given that these effects are seen in
hepatocytes immediately after addition of MEHP, is
that MEHP, or its CoA ester, is sufficiently similar to
a natural fatty acid to alter triglyceride synthesis by
allosteric effects on one or more of the enzymes in-
volved. It is worth noting that long-chain fatty acids
are known to regulate lipid synthesis and degradation
(60) and MEHP resembles a C13 fatty acid.
Either MEHP or a metabolite or, less probably, the
accumulated lipid induces the synthesis of both perox-
isomal and microsomal fatty acid oxidases. This again
would appear to be due to MEHP (or a metabolite)
mimicking a natural fatty acid, in this case acting as
inducer rather than as allosteric regulator. Interest-
ingly, a similar, though much smaller, induction of per-
oxisomal enzymes is found in rats fed a high fat diet
(61,62) and there is also marked induction in rats treated
with CPUC (ethyl-2[5(4-chloro-phenyl)pentyl]oxiran-2-
carboxylate) (63), valproic acid (64), or with citral (65)
compounds which resemble a fatty acid but with a block-
ing group which will prevent ,B-oxidation. This is con-
sistent with the proposal by Masters and Crane (66)
that medium-length fatty acids (< C14) play a principal
role in regulating peroxisomal lipid metabolism.
The increased amounts of peroxisomal fatty acid-ox-
idizing enzymes and ofthe microsomal P-450 isoenzyme-
catalyzing ,8-oxidation of fatty acids coupled with the
increased availability of both "artificial" substrate
(about 50% of ingested DEHP is excreted as a metab-
olite of MEHP produced by w-oxidation coupled with a
single round of ,B-oxidation) (67) and, possibly, of "nat-
ural" fatty acyl CoA results in greatly increased release
of active oxygen species. This may be due to either
inability ofperoxisomal catalase to cope with the amount
of hydrogen peroxide being generated by ,3-oxidation
of fatty acids and/or release of superoxides due to un-
coupling (68) of the microsomal P-450 isoenzymes re-
sponsible for X or w-1 oxidation of fatty acids. Removal
of the hydrogen peroxide (either formed in peroxisomes
or by the action of superoxide dismutase) may be re-
sponsible for the reduction in intracellular SH groups
observed in animals treated in vivo (Table 1).
The active oxygen species damage membranes by ad-
dition across double bonds in unsaturated lipids and
oxidation of SH groups, for example. In the case of the
peroxisomal membrane this results in the membrane
becoming weakened and hence there is increased fragili-
ty of peroxisomes during homogenization. Similarly,
damage to endoplasmic reticulum membranes may ex-
plain the loss of glucose-6-phosphatase activity.
The damaged membranes are removed by autophagy
resulting in the accumulation of enlarged, lipid filled,
lysosomes. The majority of these, like other lysosomes
(69), discharge into the bile canaliculi, but some re-
main-for reasons not yet clear forming lipofuscin de-
posits.
There is as yet insufficient data to propose with con-
fidence any single hypothesis to link lipofuscin accu-
mulation and the hyperplastic lesions which are the first
signs of developing tumors (70,71).
Three tentative hypotheses are as follows: (a) The
generation of active oxygen species itself results in
DNA damage. This could suggest that the peroxisome-
proliferating agents do cause mutations, albeit indi-
rectly. However, the behavior of the hyperplastic nod-
ules, both in their lack of certain enzymes, especially y-
glutamyl transpeptidase (72) and, more importantly,
their disappearance on cessation of long-term treat-
ment, suggests a difference between these compounds
and those which exert their carcinogenic effects directly
on the DNA. The liver tumors formed following treat-
ment of rats with DEHP and related compounds are
more similar to the benign adenomas which are induced
in humans by contraceptive steroids and which may
also, in a very few cases; progress to malignant tumors
(73) than to tumors formed by typical mutagenic car-
cinogens such as dimethyl nitrosamine. Therefore, al-
though the depletion of nonprotein SH groups and the
appearance of lipofuscin suggests that there is release
of active oxygen, either from peroxisomes or via un-
coupling at the endoplasmic reticulum P-450 isoen-
zymes, there is no convincing evidence that the tumors
form as a consequence of damage to DNA.
(b) A second possible hypothesis is that the tumors
form because of DNA damage, e.g., chromosomal
breaks, which arise as a result either of the burst of
mitosis which occurs immediately after the start of dos-
ing or late in life of the animal. We have observed (38)
that in rats treated with hypolipidemic drugs for 18
months there are more mitotic figures in test than in
control animals, indicating an increased rate of cell
death and replacement. The nuclei of a very high pro-
portion of the hepatocytes of aged rats and mice are
polyploid (74,75); polyploid nuclei divide with about the
same frequency as diploid (76), and it is believed that
an increase in ploidy will increase the risk of chromo-
some damage during mitosis. Furthermore, this theory
is similar to one proposed to explain the carcinogenicity
of plastic ifim implants (77). In this case the chromo-
somal damage appears to occur long before the appear-
ance of an identifiable tumor. Again, however, the re-
versal of the majority of the preneoplastic foci on
cessation of treatment would seem to weaken support
for this mechanism.
(c) A third hypothesis would connect the carcinogen-
esis by DEHP not only with that caused by other per-
oxisome-proliferating agents but also with nonmuta-
genic carcinogens such as Safrole, Ponceau MX (78),
and chlorinated hydrocarbons (79), whose principal
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short-term effects are hepatomegaly and alteration in
the endoplasmic reticulum.
It would seem likely that the burst of cell division
seen in young rats represents a natural response to the
inducing agent-effectively increasing the capacity of
the liver to detoxify the material administered. This
capacity is lost in older rats. However, in the case of
continual stimulation from chemicals such as MEHP,
there is low grade cell damage leading to an increased
rate of cell death and hepatocytes division therefore
occurs to replace those dying cells. Cells particularly
sensitive, because of random somatic mutations, to the
inducing agent or particularly insensitive to the natural
regulators of liver size will divide preferentially. This
will result in clones of cells whose size will, however,
be limited by the normal control mechanisms which gov-
ern liver growth. Subsequently further spontaneous
mutations could then reduce the sensitivity of the cells
to natural regulators resulting in a hyperplastic nodule
which does, however, like hormone-dependent tumors,
remain dependent on the presence of the inducer. Fi-
nally, and very infrequently, a further mutation results
in dependence from cell growth regulatory factors and
the formation of a frank tumor. This scheme is, of
course, analogous to the normal model for multistage
carcinogenesis. The difference is that there is no in-
crease in chemically induced damage to the DNA, so
that DEHP is not acting as a classical initiating agent
nor is DEHP acting-like a classical promoting agent-
to "fix" damage in the genome. Instead, the continued
low grade damage selects clones of cells, particularly
sensitive to the inducing agent. It is a prerequisite of
this hypothesis that the damage is mild. Hepatocyte
division will be regulated by the balance between the
cytotoxic effects of the inducer and the natural regu-
lators whose concentration varies inversely with liver
size. A large change-caused, for example, by partial
hepatectomy-will result in "indiscriminate" cell divi-
sion. Selection will only occur if the damage is pro-
longed. This theory, therefore, suggests that formation
of the hyperplastic nodules requires firstly the contin-
ued stimulation by the inducer and secondly sufficient
damage to cells to maintain an elevated rate of cell di-
visions.
Clearly, there are a number of questions regarding
the mechanisms proposed above. Firstly, why do
straight-chain phthalate esters which perturb lipid me-
tabolism in a similar way and to a similar extent to
'MEHP, not cause peroxisome proliferation? There are
differences in the metabolism of MEHP and MnOP
which might explain the difference in hepatotoxicity be-
tween the straight chain phthalates and DEHP. The
side chain of each ester is excreted as the product of w-
1 and w-oxidation. In the case ofMnOP, 21% is excreted
as the product of w-1 oxidation and 62% as the product
of w-oxidation followed by two rounds of P-oxidation
(67). In the case ofMEHP, 35% is excreted as the prod-
uct of w-1 oxidation and 30% as the product of w-oxi-
dation, only 5% of which undergoes (-oxidation (68). It
appears therefore that the presence of the ethyl group
on C2 both blocks 1-oxidation and renders MEHP a less
suitable substrate for w-oxidation and subsequent ex-
tensive (3-oxidation than MnOP. This would affect the
intracellular concentrations ofthe different esters as the
concentration of the ester in the hepatocyte will depend
on the balance between its rate of entry and its rate of
metabolism. Hence, if MnOP is more rapidly metabo-
lized, then it is possible that the intracellular concen-
tration ofMEHP is markedly higher than that ofMnOP.
A further difference is that ,B-oxidation of the w-oxi-
dation product of MnOP will release acetyl CoA. Given
the difference in structure between a normal fatty acid
and the dicarboxylic acid deriving from w-oxidation of
MnOP, it is possible that the latter will evade the normal
control which govern oxidation of fatty acids and sugars
so that excess acetyl CoA will be formed. A similar
modification in metabolism is thought to occur after
ingestion of ethanol, and it is, perhaps, not surprising
therefore that the lesion produced by DnOP in rats re-
sembles that produced in humans by ethanol.
A second major objection to the proposed mechanism
of action is that while the mechanism given above sug-
gests that greatly increased amounts of hydrogen per-
oxide are evolved following treatment of rats with
DEHP, direct experiments with hepatocytes gave no
evidence of any such change. It should be noted, how-
ever, that cultured hepatocytes showed neither the fall
in glucose-6-phosphatase activity found in vivo nor do
they show any reduction in glutathione levels, whereas
in vivo nonprotein SH groups are significantly reduced.
A possible cause for the discrepancy is that the culture
medium provides a predominantly reducing environ-
ment (due to the presence of cysteine) as opposed to
the essentially oxidizing nature of blood. However, this
remains to be substantiated. It does, however, seem
clear that hepatocytes in vitro do not at the present
time serve as an adequate model for the third stage in
the development of the lesion.
We would, therefore, conclude that while the pattern
of development of liver damage in rats treated with
DEHP is consistent with the mechanism discussed by
Reddy and Lalwani (2), namely, that increased produc-
tion of hydrogen peroxide arising from increased turn-
over of the fatty acid-oxidizing system of peroxisomes
is an essential part of the process of liver damage. How-
ever, there is as yet no direct evidence that peroxisome
proliferation or active oxygen generation, in them-
selves, are linked with the ultimate development of he-
patocellular adenomas and carcinomas. We propose that
both peroxisome proliferators such as DEHP and agents
such as chlorinated hydrocarbons which cause both in-
duction of endoplasmic reticulum oxidases and liver
damage be grouped together and that the tumors which
they cause, like those caused by certain hormnones (80),
be considered to arise by an epigenetic mechanism in-
volving breakdown of the normal homeostatic mecha-
nism-in the case of DEHP, the balance between he-
patocellular proliferation in response to persistent
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xenobiotic exposure and the normal controls governing
liver size.
Effects of Phthalic Acid Esters on the
Thyroid
Our results show that agents which cause peroxisome
proliferation in the liver join an already extensive list
ofchemicals which alter the metabolism ofboth the liver
and of the thyroid gland, other examples being chlori-
nated hydrocarbons such as the polychlorinated bi-
phenyls (47) and barbiturates (81). The results of treat-
ment are, in all cases, associated with an increased
activity in the thyroid gland, accompanied by a lowering
of plasma T4 but with plasma T3 remaining close to
control values. Our results, which show that short-term
thyroid changes are produced both by the peroxisome-
proliferating ester di-2(ethylhexyl) phthalate and by its
straight-chain analogs di(n-octyl) phthalate and di (n-
hexyl) phthalate which do not cause proliferation of he-
patic peroxisomes, emphasize that the risk of thyroidal
changes is not restricted to compounds or to species
which show proliferation of peroxisomes.
In spite ofmany studies there is no agreed mechanism
for the linkage between hepatic and thyroidal effects of
inducers of microsomal oxidases such as polychlorinated
biphenyls or barbiturates. There are several indications
that the linkage may be associated with the increased
rate of excretion of the hornone which has been ob-
served both with groups of compounds (81-83); but
whereas with polychlorinated biphenyls (82) and poly-
cyclic hydrocarbons (83) the increase would appear due
to increased glucuronyl transferase activity, this is not
the case in rats treated with phenobarbital. Another
possible correlate is displacement of thyroxine from
binding proteins. The association between low plasma
T4 and a clinically euthyroid state is reminiscent of hu-
man patients treated with diphenylhydantoin (84), and
indeed polychlorinated biphenyls appear to displace thy-
roxine from binding proteins (82) as does clofibrate (85).
There is considerable evidence that whereas for most
purposes T4 is essentially a prohormone, the regulation
of TSH synthesis reflects the concentration of T4 in
plasma not of T3 (86). Hence, it is possible that this
combination of a clinically euthyroid state with low
plasma T4 and hyperactivity of the thyroid gland is due
to the combination of a high proportion of binding sites
for thyroxine by the toxin, resultinrg in a reduced total
plasma T4. This, in turn, results in stimulation of TSH
production and, hence, of thyroxine synthesis, but this
is counterbalanced by peripheral conversion to T3 (87)
and by an increase in excretion through the liver. There
are, however, many other mechanisms that may connect
alterations in the liver and thyroid and considerably
more experimental data is required before more than
outline hypothesis can be formulated. It should, how-
ever, be noted that, with polychlorinated biphenyls, it
is known that thyroidal changes are induced in man (88).
Our results show that the thyroidal changes induced by
phthalate esters is induced by agents which do not in-
duce peroxisome proliferation. Hence, it is not currently
possible to use the extensive epidemiological data gath-
ered to hypolipidemic compounds (89) to assess whether
there is any risk to man.
Conclusion
Our experiments suggest a connection between the
early hepatic changes observed in rats (liver enlarge-
ment and proliferation of hepatic peroxisomes) and the
subsequent development of liver tumors. The changes
which occur in the livers are consistent with an epige-
netic mechanism of carcinogenesis. This is supported by
the appearance of the tumors (well differentiated, with,
no or few metastases) which resemble that ofthe benign
adenomas which occur occasionally in women taking
contraceptive steroids. In view of the apparent connec-
tion in rats between the short-term effects in liver and
subsequent tumorigenesis, the identification that the'
no-effect level for pathological changes in rat liver oc--
curs at relatively high doses and the evidence that hu-
mans treated with hypolipidemic drugs (90) or mar-
mosets treated with DEHP (91) do not show the typical
short-term liver changes produced by these compounds
in rats, it would seem unlikely that the low environ-
mental levels of DEHP to which man is exposed pose
a significant risk of liver cancer in humans. For humans
exposed over short periods to rather higher levels of
DEHP (e.g., by blood transfusions) the situation is less
clear-cut, and effects on liver and thyroid function could
arise. It would seem unwise to attempt substitution of
DEHP by straight-chain analogs without carefullymon-
itoring, for it is clear that although the hepatic effects
are different from those of DEHP they may give none-
theless grounds for concern.
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